MINIMED GRP INC. O.N.

MiniMed reported Q4 2026 revenue of USD 837 million (+8.7% organic) and adjusted EBITDA of USD 154 million (+32%), with the EBITDA margin rising to 18.4%. Full-year revenue exceeded USD 3 billion for the first time, with organic growth of 8%, driven by international markets (+12.2%), while U.S. growth was only 1.5% due to timing effects from the early FDA approval of the MiniMed Flex. The stock reacted positively and rose after the results, and the company forecasts further revenue and EPS growth for 2027 as well as product launches such as MiniMed Flex and MiniMed Fit. » More on de.investing.com

MiniMed announced an expanded agreement with Abbott to market dual glucose‑ketone sensors that will be exclusively integrated into MiniMed’s smart dosing systems to detect rising ketone levels and diabetic ketoacidosis early. The new sensors are the same size as the Instinct sensor; Abbott recently received CE marking and the system is currently under FDA review. MiniMed has seen recent share gains but remains down year‑to‑date; analysts see upside potential with price targets of $16–$26 and forecast a return to profitability this year. » More on de.investing.com

On March 18, MiniMed received FDA approval for the smartphone-controlled insulin pump MiniMed Flex, allowing an accelerated market launch in the U.S. Under an agreement with Blackstone, MiniMed will in the first two years after approval either pay royalties or make a minimum payment of $157 million. The company plans to record this minimum amount as a one-time charge in the fourth quarter of fiscal year 2026. » More on de.investing.com